Valneva SE (VALN) Receivables (2020 - 2026)
Valneva SE (VALN) posted Receivables of $11.9 million for Q1 2026, down 63.36% sequentially from $32.4 million in Q4 2025, and down 66.36% YoY from $35.3 million in Q1 2025.
Analysis
Valneva SE (VALN) Receivables (2020 - 2026) Analysis & Trends
Valneva SE has reported Receivables for 7 years, with the latest figure at $11.9 million in Q1 2026.
- Quarterly Receivables fell 66.36% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 66.36% YoY) and the FY2025 annual result came in at $32.4 million, down 11.42% from the prior year.
- Receivables fell to $11.9 million in Q1 2026 per VALN's latest filing, from $32.4 million in the prior quarter.
- Over five years, Receivables peaked at $58.2 million in Q3 2022 and troughed at $197095.3 in Q2 2023.
- A 5-year average of $30.1 million and a median of $29.6 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables sank 98.86% in 2023, then soared 16612.1% in 2024.
- Over 5 years, Receivables stood at $24.5 million in 2022, then soared by 76.66% to $43.3 million in 2023, then slipped by 16.57% to $36.1 million in 2024, then declined by 10.28% to $32.4 million in 2025, then sank by 63.36% to $11.9 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $11.9 million, $32.4 million, and $23.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 18.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.99 Mn |
| Mar 31, 2026 | 11.86 Mn |
| Dec 31, 2025 | 32.38 Mn |
| Sep 30, 2025 | 23.47 Mn |
| Jun 30, 2025 | 27.31 Mn |
| Mar 31, 2025 | 35.26 Mn |
| Dec 31, 2024 | 37.62 Mn |
| Sep 30, 2024 | 33.34 Mn |
| Jun 30, 2024 | 32.94 Mn |
| Mar 31, 2024 | 29.64 Mn |
| Dec 31, 2023 | 44.88 Mn |
| Sep 30, 2023 | 48.27 Mn |
| Jun 30, 2023 | 36.80 Mn |
| Mar 31, 2023 | 29.00 Mn |
| Dec 31, 2022 | 24.48 Mn |
| Sep 30, 2022 | 58.21 Mn |
| Jun 30, 2022 | 17.34 Mn |
| Mar 31, 2022 | 28.13 Mn |
| Dec 31, 2021 | 50.37 Mn |
| Dec 31, 2020 | 22.94 Mn |